Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16-26 years in Japan: a randomised, double-blind, placebo-controlled trial.

Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/42546724

Akira Wakana; Alain Luxembourg; Anna R Giuliano; Keiko Wan; Koji Hisamoto; Masaki Yamanaka; Masayasu Nomura; Miyuki Sawata; Nobufumi Kanno; Nobuyuki Oshima; Yoshiyuki Tanaka; Yukako Fukao

Aug 4, 2026